Search
Autolus Therapeutics PLC
AUTLAdd to Watchlist
1.665USD
+0.175+11.74%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
443.13MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-22The current earnings forecast score of Autolus Therapeutics PLC is 8.73, ranking 69 out of 389 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 13.00 and a low of 5.00.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
8.440
Target Price
+466.44%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Autolus Therapeutics PLC
AUTL
11
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Autolus Therapeutics PLC's expected revenue for the next quarter?
Autolus Therapeutics PLC's expected revenue is 30.24M.
What is Autolus Therapeutics PLC's price target?
Analysts forecast that Autolus Therapeutics PLC's price target is USD 10.00, with the highest forecast at USD 13.00 and the lowest forecast at USD 5.00.
How have Autolus Therapeutics PLCAUTL's recent earnings per share performed?
The market expectation was USD -0.27, while Autolus Therapeutics PLCAUTL's earnings per share (EPS) for the previous quarter was USD -0.34. EPS for the next quarter is expected at USD -0.23.
What is the analyst rating for Autolus Therapeutics PLC?
Based on the ratings of Autolus Therapeutics PLC's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
